Alnylam Pharmaceuticals(ALNY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ALNY Alnylam Pharmaceuticals

Closed Martin Luther King, Jr. Day 01-16 16:00:00 EST

359.27

+0.01

+0.00%

盘后359.00

-0.27-0.08%

19:42 EST

High367.20	Low355.46	Vol1.53M
Open362.29	D1 Closing359.26	Amplitude3.27%
Mkt Cap47.46B	Tradable Cap45.32B	Total Shares132.11M
T/O548.85M	T/O Rate1.21%	Tradable Shares126.15M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ALNY","market":"US","secType":"STK","nameCN":"Alnylam Pharmaceuticals","latestPrice":359.27,"timestamp":1768597200000,"preClose":359.26,"halted":0,"volume":1527370,"hourTrading":{"tag":"盘后","latestPrice":359,"preClose":359.27,"latestTime":"19:42 EST","volume":174575,"amount":62718869.2197,"timestamp":1768610527818,"change":-0.27,"changeRate":-0.000752,"amplitude":0},"delay":0,"changeRate":0.000027834994154625913,"floatShares":126154848,"shares":132113818,"eps":0.329855,"marketStatus":"Closed Martin Luther King, Jr. Day","change":0.01,"latestTime":"01-16 16:00:00 EST","open":362.29,"high":367.2,"low":355.46,"amount":548847640.6868,"amplitude":0.032678,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.329855,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1768899600000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1085630400000,"exchange":"NASDAQ","adjPreClose":359.26,"preHourTrading":{"tag":"盘前","latestPrice":360.95,"preClose":359.26,"latestTime":"09:29 EST","volume":313,"amount":112706.2607,"timestamp":1768573770050,"change":1.69,"changeRate":0.004704,"amplitude":0.024133},"postHourTrading":{"tag":"盘后","latestPrice":359,"preClose":359.27,"latestTime":"19:42 EST","volume":174575,"amount":62718869.2197,"timestamp":1768610527818,"change":-0.27,"changeRate":-0.000752,"amplitude":0},"volumeRatio":0.8452347642709607,"impliedVol":0.4365,"impliedVolPercentile":0.5339},"requestUrl":"/m/hq/s/ALNY","defaultTab":"news","newsList":[{"id":"2604151179","title":"Alnylam Pharmaceuticals on Track for Lowest Close Since July -- Data Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2604151179","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604151179?lang=en_us&edition=fundamental","pubTime":"2026-01-17 03:23","pubTimestamp":1768591380,"startTime":"0","endTime":"0","summary":"Alnylam Pharmaceuticals, Inc  is currently at $358.27, down $0.99 or 0.28%. --Would be lowest close since July 30, 2025, when it closed at $339.80. --On pace for largest percent decrease since Jan. 15, 2026, when it fell 2.07%. --Currently down seven consecutive days; down 15.2% over this period. --Longest losing streak since Feb. 18, 2025, when it fell for seven straight trading days. --Down 27.07% from its all-time closing high of $491.22 on Oct. 20, 2025. --Up 45.48% from 52 weeks ago , when it closed at $246.27. --Up 59.71% from its 52-week closing low of $224.32 on April 8, 2025. --Seventh least active stock in the Nasdaq 100 today","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU0889565916.HKD","BK4585","LU0109394709.USD","LU0114720955.EUR","LU0320765992.SGD","LU0882574055.USD","BK4548","ALNY","BK4139"],"gpt_icon":0},{"id":"2603551642","title":"Alnylam EVP and Chief Commercial Officer Tolga Tanguler Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2603551642","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603551642?lang=en_us&edition=fundamental","pubTime":"2026-01-15 05:23","pubTimestamp":1768425783,"startTime":"0","endTime":"0","summary":"Tolga Tanguler, EVP and Chief Commercial Officer of Alnylam Pharmaceuticals Inc., has reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alnylam Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 14, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260114:nNDL2qMLTs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Alnylam EVP and Chief Commercial Officer Tolga Tanguler Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0114720955.EUR","BK4588","LU0109394709.USD","BK4139","BK4548","LU0889565916.HKD","ALNY","LU0882574055.USD","LU0320765992.SGD","BK4585"],"gpt_icon":0},{"id":"2603642557","title":"Alnylam CSO Kevin Fitzgerald Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2603642557","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603642557?lang=en_us&edition=fundamental","pubTime":"2026-01-15 05:22","pubTimestamp":1768425751,"startTime":"0","endTime":"0","summary":"Kevin Joseph Fitzgerald, CSO & EVP, Head of Research at Alnylam Pharmaceuticals Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alnylam Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 14, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260114:nNDL9ftbl4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU0320765992.SGD","BK4139","BK4548","LU0889565916.HKD","LU0882574055.USD","LU0114720955.EUR","BK4588","ALNY","LU0109394709.USD"],"gpt_icon":0},{"id":"2603069545","title":"Bernstein Reaffirms Their Buy Rating on Alnylam Pharma (ALNY)","url":"https://stock-news.laohu8.com/highlight/detail?id=2603069545","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603069545?lang=en_us&edition=fundamental","pubTime":"2026-01-14 16:36","pubTimestamp":1768379773,"startTime":"0","endTime":"0","summary":"Bernstein analyst William Pickering maintained a Buy rating on Alnylam Pharma yesterday and set a price target of $491.00. The company’s shares clo...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/bernstein-reaffirms-their-buy-rating-on-alnylam-pharma-alny-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/bernstein-reaffirms-their-buy-rating-on-alnylam-pharma-alny-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALNY"],"gpt_icon":0},{"id":"2603339326","title":"Evercore ISI Sticks to Its Buy Rating for Alnylam Pharma (ALNY)","url":"https://stock-news.laohu8.com/highlight/detail?id=2603339326","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603339326?lang=en_us&edition=fundamental","pubTime":"2026-01-13 22:47","pubTimestamp":1768315628,"startTime":"0","endTime":"0","summary":"In a report released today, Cory Kasimov from Evercore ISI maintained a Buy rating on Alnylam Pharma, with a price target of $515.00. According to ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/evercore-isi-sticks-to-its-buy-rating-for-alnylam-pharma-alny-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/evercore-isi-sticks-to-its-buy-rating-for-alnylam-pharma-alny-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALNY"],"gpt_icon":0},{"id":"2603753681","title":"Analysts Are Bullish on Top Healthcare Stocks: Alnylam Pharma (ALNY), Foghorn Therapeutics (FHTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2603753681","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603753681?lang=en_us&edition=fundamental","pubTime":"2026-01-13 20:50","pubTimestamp":1768308630,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Alnylam Pharma (ALNY – Research Report) and Foghorn ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-alnylam-pharma-alny-foghorn-therapeutics-fhtx-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-alnylam-pharma-alny-foghorn-therapeutics-fhtx-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0320765992.SGD","BK4588","LU0114720955.EUR","LU0128526141.USD","BK4548","ALNY","FHTX","LU0109394709.USD","LU0882574055.USD","BK4137","LABU","LU0889565916.HKD","BK4112","BK4581","BK4585","BK4139","XBI","LU0029874061.USD"],"gpt_icon":0},{"id":"2603528798","title":"Alnylam Lays Out 2030 Vision, Bets On TTR Leadership And Pipeline Scale","url":"https://stock-news.laohu8.com/highlight/detail?id=2603528798","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603528798?lang=en_us&edition=fundamental","pubTime":"2026-01-13 02:33","pubTimestamp":1768242780,"startTime":"0","endTime":"0","summary":"Alnylam outlines its 2030 strategy, targeting TTR leadership, pipeline expansion, and strong revenue growth backed by rising product sales.","market":"hk","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/01/12/Alnylam-Pharmaceuticals-Photo-via-Shutte.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/01/12/Alnylam-Pharmaceuticals-Photo-via-Shutte.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/markets/guidance/26/01/49855001/alnylam-lays-out-2030-vision-bets-on-ttr-leadership-and-pipeline-scale","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/guidance/26/01/49855001/alnylam-lays-out-2030-vision-bets-on-ttr-leadership-and-pipeline-scale","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["LU0114720955.EUR","BK4139","LU0889565916.HKD","LU0109394709.USD","ALNY","LU0320765992.SGD","LU0882574055.USD","BK4588","BK4585","BK4548"],"gpt_icon":0},{"id":"2603544296","title":"Alnylam 2026 guidance reflects continued momentum, says H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2603544296","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603544296?lang=en_us&edition=fundamental","pubTime":"2026-01-13 00:10","pubTimestamp":1768234246,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Patrick Trucchio notes Alnylam (ALNY) pre-announced Q4 and 2025 net product revenue results and gave a net product revenue ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/alnylam-2026-guidance-reflects-continued-momentum-says-h-c-wainwright-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/alnylam-2026-guidance-reflects-continued-momentum-says-h-c-wainwright-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0320765992.SGD","BK4548","BK4585","BK4588","LU0109394709.USD","LU0882574055.USD","LU0889565916.HKD","BK4139","ALNY","LU0114720955.EUR"],"gpt_icon":0},{"id":"2603544629","title":"BUZZ - Nasdaq top and bottom performing stocks at about 11:01 a.m. EST on 2026-01-12","url":"https://stock-news.laohu8.com/highlight/detail?id=2603544629","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603544629?lang=en_us&edition=fundamental","pubTime":"2026-01-13 00:01","pubTimestamp":1768233667,"startTime":"0","endTime":"0","summary":"BUZZ - Nasdaq top and bottom performing stocks at about 11:01 a.m. EST on 2026-01-12Nasdaq 100 .NDXTop PerformersPercent ChangeDexcom Inc DXCM.OQ+6.4%Comcast Corp CMCSA.OQ+2.5%O'Reilly Automotive Inc ORLY.OQ+2.2%Advanced Micro Devices Inc AMD.OQ+2.1%Strategy Inc MSTR.OQ+1.8%Bottom PerformersPercent ChangeAlnylam Pharmaceuticals Inc ALNY.OQ-9.6%Insmed Inc INSM.OQ-4.3%Qualcomm Inc QCOM.OQ-3.1%Intuitive Surgical Inc ISRG.OQ-2.9%Analog Devices Inc ADI.OQ-2.1%The Nasdaq 100 .NDX lost 22.22 points, or 0.09%, to 25,744.04 and recorded 6 new highs and one new low. 39 stocks rose and 63 fell as declining issues outnumbered advancers by about a 1.6-to-1 ratio.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nL8N3YD1IN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1489326972.SGD","LU2264538146.SGD","IE00BMPRXR70.SGD","09799","IE00B19Z9P08.USD","LU0312595415.SGD","LU0127658192.USD","LU0985489474.SGD","IE00B19Z8X17.USD","LU0082616367.USD","LU1057294990.SGD","MSTW","LU2360106780.USD","BK4605","LU0823421333.USD","LU2324357040.USD","LU2125909593.SGD","MSII","LU2098885051.SGD","SG9999001440.SGD","WNTR","LU0719512351.SGD","BK4614","BK4595","LU1267930573.SGD","LU1804176565.USD","LU1989764748.USD","LU1989764664.SGD","LU1815336760.USD","LU0708994859.HKD","LU0096364046.USD","BK4023","LU1868836914.USD","LU1670710661.SGD","ADI","IE0004445239.USD","BK4515","LU0198837287.USD","IE00BZ199S13.USD","BK4141","LU0354030511.USD","LU1880398471.USD","MSST","LU0942090050.USD","LU0170899867.USD","3LMI.UK","LU0868494617.USD","LU0724618433.USD","BK4575","BK4554","ALNY","IMST","LU1242518931.SGD","LU2089985449.USD","LU1316542783.SGD","BK4598","LU1244550221.USD","LU1496350502.SGD","LU1119994496.HKD","LU0130102774.USD","GB00BDT5M118.USD","LU1868836757.USD","LU1150488135.SGD","07399","LU1201861249.SGD","LU1061106388.HKD","LU2931357623.SGD","LU1868836591.USD","LU0238689110.USD","BK4548","LU0878866978.SGD","BK4512","IE00B5TLWC47.USD","LU0058720904.USD","LU0068578508.USD","IE00BVYPNQ40.USD","LU0823421416.USD","LU1670711040.USD","LU1974910355.USD","IE00B19Z9505.USD","BK4507","IE00B19Z9Z06.USD","LU1992135399.USD","LU2237443382.USD","MSDD","LU2272731600.USD","MSTZ","LU1366192091.USD","LU0868494708.USD","BK4585","LU1868837300.USD","LU2265009873.SGD","LU1303367103.USD","MSTX","IE00BFXG0V08.USD","INSM","LU0320765489.SGD","MSOO","LU1244550577.SGD","BK4596","BK4529","CMCSA","IE00BYQQ9H92.USD","LU0070302665.USD","LU2237438978.USD","SG9999002232.USD","SG9999015952.SGD","LU1670710588.SGD","LU1951200564.SGD","LU2247934214.USD","LU1880398554.USD","LU1917777945.USD","LU0289739699.SGD","BK4214","BK4561","BK4527","IE00B19Z8W00.USD","LU0053671581.USD","LU0266013472.USD","LU1084165304.USD","LU2272731782.SGD","BK4600","LU1852331112.SGD","LU1035775433.USD","LU0122379950.USD","LU0390134368.USD","LU2458330169.SGD","LU2054465674.USD","LU2237443622.USD","NDX","BK4573","LU0314104364.USD","LU2237443549.SGD","SG9999015945.SGD","LU1242518857.USD","IE00BSNM7G36.USD","BK4082","LU1868837136.USD","LMI3.UK","LU2250418816.HKD","SG9999002224.SGD","BK4551","IE00B5949003.HKD","MTYY","LU1261432733.SGD","LU0081259029.USD","LU1988902786.USD","LU2360107325.USD","MSTK","SG9999015986.USD","IE00B894F039.SGD","LU1823568750.SGD","LU1894683348.USD","MSTY","LU2298322129.HKD","MST","MSTY.UK","LU1923622614.USD","LU0056508442.USD","BK4604","LU1046421795.USD","LU1861559042.SGD","BK4566","BK4579","LU1978683503.SGD","09399","LU2063271972.USD","LU1803068979.SGD","IE0009356076.USD","LU1244550494.USD","LU0061475181.USD","LU1064131342.USD","LU2133065610.SGD","SMI3.UK","LU0889565916.HKD","LU2458330243.SGD","3SMI.UK","LU1069344957.HKD","LU1992135472.HKD","LU2433249047.HKD","SMST","LU1642822529.SGD","BK4504","LU2275660780.HKD","BK4139","LU0124384867.USD","LU1951198990.SGD","BK4588","ORLY","LU1059921491.USD","LU1323610961.USD","IE00BGHQDM52.EUR","LU0320765992.SGD","LU0642271901.SGD","LU1894683264.USD","LU0109394709.USD","LU0302445910.USD","LU2211815571.USD","LU1074936037.SGD","LU2106854487.HKD","LU0957808578.USD","LU2023250504.SGD","BK4534","07799","LU0444971666.USD","LU0648001328.SGD","LU1861558580.USD","LU2125909247.SGD","BK4516","LU0889565833.HKD","BK4543","LU0079474960.USD","LU0823416689.USD","LU1861219969.SGD","BK4550","LU0114720955.EUR","LU0823434583.USD","LU0882574055.USD","LU1670711123.USD","LU0208291251.USD","LU0109392836.USD","LU0979878070.USD","IE00BD6J9T35.USD","LU0097036916.USD","LU0310800379.SGD","LU0980610538.SGD","BK4581","ISRG","LU2023250843.SGD","LU0354030438.USD","APED","LU2237443978.SGD","DXCM","LU1023059063.AUD","SG9999001424.SGD","LU0274383776.USD","LU2355687059.USD",".IXIC","IE00BMPRXN33.USD","LU0029864427.USD","MSTP","BK4532","BK4612","IE00BVYPNP33.GBP","LU0128525929.USD","LU1861214812.USD","LU1150488218.USD","LU1983299246.USD","BK4100","LU1923623000.USD","LU0823434740.USD","LU0433182093.SGD","SG9999015978.USD","LU2112291526.USD"],"gpt_icon":1},{"id":"2602517393","title":"Alnylam price target lowered to $529 from $530 at BofA","url":"https://stock-news.laohu8.com/highlight/detail?id=2602517393","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602517393?lang=en_us&edition=fundamental","pubTime":"2026-01-12 20:39","pubTimestamp":1768221599,"startTime":"0","endTime":"0","summary":"BofA analyst Tazeen Ahmad lowered the firm’s price target on Alnylam (ALNY) to $529 from $530 and keeps a Buy rating on the shares after the compan...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/alnylam-price-target-lowered-to-529-from-530-at-bofa-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/alnylam-price-target-lowered-to-529-from-530-at-bofa-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0320765992.SGD","LU0889565916.HKD","BK4588","LU0114720955.EUR","BK4548","LU0882574055.USD","BK4139","LU0109394709.USD","ALNY","BK4585"],"gpt_icon":0},{"id":"2602173345","title":"Alnylam sees FY26 net product revenue guidance $4.9B-$5.3B","url":"https://stock-news.laohu8.com/highlight/detail?id=2602173345","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602173345?lang=en_us&edition=fundamental","pubTime":"2026-01-12 20:35","pubTimestamp":1768221356,"startTime":"0","endTime":"0","summary":"Alnylam (ALNY) announced full year 2026 combined net product revenue guidance for AMVUTTRA, ONPATTRO, GIVLAARI and OXLUMO of $4.9B-$5.3B, represent...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/alnylam-sees-fy26-net-product-revenue-guidance-4-9b-5-3b-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/alnylam-sees-fy26-net-product-revenue-guidance-4-9b-5-3b-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4548","BK4139","LU0114720955.EUR","ALNY","BK4588","LU0882574055.USD","LU0889565916.HKD","LU0109394709.USD","BK4585","LU0320765992.SGD"],"gpt_icon":0},{"id":"2602519284","title":"Alnylam Pharmaceuticals Is Maintained at Buy by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2602519284","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602519284?lang=en_us&edition=fundamental","pubTime":"2026-01-12 19:21","pubTimestamp":1768216860,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ALNY/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 12, 2026 06:21 ET (11:21 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALNY"],"gpt_icon":0},{"id":"2602568727","title":"Alnylam Launches \"Alnylam 2030\" Strategy to Drive Next Era of Growth and Patient Impact","url":"https://stock-news.laohu8.com/highlight/detail?id=2602568727","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602568727?lang=en_us&edition=fundamental","pubTime":"2026-01-12 06:09","pubTimestamp":1768169381,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260111:nFWN3YA0ZJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0320765992.SGD","LU0882574055.USD","ALNY","BK4585","BK4588","LU0109394709.USD","LU0889565916.HKD","LU0114720955.EUR","BK4139","BK4548"],"gpt_icon":0},{"id":"2602156803","title":"Alnylam Pharmaceuticals Inc - Net Product Revenues for Amvuttra and Onpattro for Q4 Were Approximately $827 Mln and $32 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2602156803","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602156803?lang=en_us&edition=fundamental","pubTime":"2026-01-12 06:09","pubTimestamp":1768169381,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260111:nFWN3YA0ZJ:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4585","LU0109394709.USD","BK4548","ALNY","LU0889565916.HKD","LU0320765992.SGD","LU0882574055.USD","LU0114720955.EUR","BK4588","BK4139"],"gpt_icon":0},{"id":"2602256822","title":"Alnylam Projects 2026 Net Product Revenue Up to $5.3 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=2602256822","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602256822?lang=en_us&edition=fundamental","pubTime":"2026-01-12 06:00","pubTimestamp":1768168837,"startTime":"0","endTime":"0","summary":"Alnylam Pharmaceuticals Inc. has announced its financial outlook as part of its new five-year \"Alnylam 2030\" strategy. The company reported preliminary full year 2025 net product revenues of $2,987 million, representing an 81% increase compared to 2024. This growth is driven primarily by total TTR  revenues, which are expected to reach $2,487 million in 2025, reflecting a 103% increase versus the prior year. Looking ahead, Alnylam provided 2026 combined net product revenue guidance in the range of $4,900 million to $5,300 million, with TTR net product revenues projected between $4,400 million and $4,700 million. The company attributes this significant growth to the continued expansion of its commercial product portfolio and advancement of its RNAi therapeutics pipeline.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purp","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260111:nNDL2ZZ6kx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4548","BK4588","BK4139","BK4585","LU0882574055.USD","ALNY","LU0114720955.EUR","LU0109394709.USD","LU0320765992.SGD","LU0889565916.HKD"],"gpt_icon":0},{"id":"2602525305","title":"Will Alnylam’s New Five‑Year Roadmap and Early 2025 Revenue Update Redefine Its GARP Story (ALNY)?","url":"https://stock-news.laohu8.com/highlight/detail?id=2602525305","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602525305?lang=en_us&edition=fundamental","pubTime":"2026-01-11 22:16","pubTimestamp":1768140968,"startTime":"0","endTime":"0","summary":"Alnylam Pharmaceuticals recently outlined plans, now in the past, to present a company overview, early 2025 revenue figures, and a new five-year strategy at the 44th Annual J.P. Morgan Healthcare Conference, including an outlook for 2026 product sales via a live webcast.\nThis update comes as the company is viewed as financially disciplined with net cash, strong free cash flow conversion from EBIT, and interest in its growth-at-a-reasonable-price profile.\nWe’ll now examine how anticipation...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alny/alnylam-pharmaceuticals/news/will-alnylams-new-fiveyear-roadmap-and-early-2025-revenue-up","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alny/alnylam-pharmaceuticals/news/will-alnylams-new-fiveyear-roadmap-and-early-2025-revenue-up","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ALNY","GARP"],"gpt_icon":0},{"id":"2602399986","title":"Alnylam Pharmaceuticals Is Maintained at Buy by Truist Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2602399986","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602399986?lang=en_us&edition=fundamental","pubTime":"2026-01-09 00:52","pubTimestamp":1767891120,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ALNY/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 08, 2026 11:52 ET (16:52 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALNY"],"gpt_icon":0},{"id":"2601528364","title":"Alnylam price target lowered to $530 from $535 at Truist","url":"https://stock-news.laohu8.com/highlight/detail?id=2601528364","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601528364?lang=en_us&edition=fundamental","pubTime":"2026-01-08 20:56","pubTimestamp":1767877003,"startTime":"0","endTime":"0","summary":"Truist lowered the firm’s price target on Alnylam (ALNY) to $530 from $535 and keeps a Buy rating on the shares. The firm updated its model, but te...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/alnylam-price-target-lowered-to-530-from-535-at-truist-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/alnylam-price-target-lowered-to-530-from-535-at-truist-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0320765992.SGD","LU0889565916.HKD","LU0109394709.USD","BK4139","BK4548","BK4585","LU0114720955.EUR","LU0882574055.USD","BK4588","ALNY"],"gpt_icon":0},{"id":"2601038913","title":"Alnylam Pharmaceuticals Files Initial Beneficial Ownership Statement for Director Stuart A. Arbuckle","url":"https://stock-news.laohu8.com/highlight/detail?id=2601038913","media":"Reuters","labels":["executive","shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601038913?lang=en_us&edition=fundamental","pubTime":"2026-01-08 05:17","pubTimestamp":1767820638,"startTime":"0","endTime":"0","summary":"Alnylam Pharmaceuticals Inc. has filed an initial statement of beneficial ownership  with the U.S. Securities and Exchange Commission. The filing lists Stuart A. Arbuckle as a Director of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alnylam Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 07, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nNDL2p7rl9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Alnylam Pharmaceuticals Files Initial Beneficial Ownership Statement for Director Stuart A. Arbuckle","news_tag":"executive,shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0114720955.EUR","BK4139","LU0889565916.HKD","LU0109394709.USD","ALNY","LU0320765992.SGD","LU0882574055.USD","BK4588","BK4585","BK4548"],"gpt_icon":0},{"id":"2601802255","title":"BUZZ - Nasdaq top and bottom performing stocks at about 11:01 a.m. EST on 2026-01-07","url":"https://stock-news.laohu8.com/highlight/detail?id=2601802255","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601802255?lang=en_us&edition=fundamental","pubTime":"2026-01-08 00:01","pubTimestamp":1767801667,"startTime":"0","endTime":"0","summary":"BUZZ - Nasdaq top and bottom performing stocks at about 11:01 a.m. EST on 2026-01-07Nasdaq 100 .NDXTop PerformersPercent ChangeIntel Corp INTC.OQ+8.9%Alnylam Pharmaceuticals Inc ALNY.OQ+4.8%CrowdStrike Holdings Inc CRWD.OQ+4.7%Strategy Inc MSTR.OQ+4.7%Datadog Inc DDOG.OQ+4.3%Bottom PerformersPercent ChangeWestern Digital Corp WDC.OQ-8.0%Seagate Technology Holdings PLC STX.OQ-7.2%Versant Media Group Inc VSNT.OQ-4.7%Marvell Technology Inc MRVL.OQ-4.5%CoStar Group Inc CSGP.OQ-3.3%The Nasdaq 100 .NDX gained 98.47 points, or 0.38%, to 25,738.18 and recorded 4 new highs and 4 new lows. 47 stocks rose and 55 fell as declining issues outnumbered advancers by about a 1.2-to-1 ratio.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nL8N3Y81AR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0390134368.USD","BK4607","SG9999000418.SGD","LU0154236417.USD","LU2244417387.USD","IE00BN8TJ469.HKD","04335","BK4613","LU2458330243.SGD","LU0882574055.USD","LU0889565916.HKD","LU1951198990.SGD","LU1992135472.HKD","BK4585","BK4516","MSTY","LU2458330169.SGD","BK4605","LU2095319765.USD","LU1670628061.USD","IE0004445239.USD","LU0823421333.USD","BK4527","LU1989764664.SGD","BK4515","LU1084165304.USD","BK4533","VSNT","LU2265009873.SGD","LU0444971666.USD","LU2125909593.SGD","MSTX","LU2272731600.USD","BK4532","LU1989764748.USD","IE00BMPRXN33.USD","ALNY","LU1804176565.USD","CRWD","LU1670627923.USD","LU1303367103.USD","LU1917777945.USD","LU0109391861.USD","BK4535","BK4551","BK4550","APED","SMI3.UK","BK4097","BK4602","LU0320765059.SGD","09399","07399","LU0081259029.USD","LU1720051108.HKD","LU1923622291.USD","BK4595","IE00BZ9MQY76.HKD","LU0114720955.EUR","BK4139","07799","IE00BLSP4239.USD","LU1064131342.USD","MSTP","LU2473716301.USD","LU0274383776.USD","LU2089985449.USD","09799","LU0823421416.USD","BK4561","LU1169590202.USD","MSTY.UK","LU1046421795.USD","LU1974910355.USD","MTYY","MST",".IXIC","IE00B894F039.SGD","LU0345774391.USD","LU0957808578.USD","LU1169589451.USD","LU1316542783.SGD","LU1861220033.SGD","MSTW","BK4023","LU1119994496.HKD","LU1992135399.USD","LU0203345920.USD","CSGP","LU1823568750.SGD","LU1548497426.USD","3SMI.UK","MSII","LU2211815571.USD","LU2023250504.SGD","BK4612","LU0154245756.USD","LU1815336760.USD","LU2322448791.USD","MSTZ","SMST","BK4554","LU0056508442.USD","LU2322448957.HKD","LU2210149790.SGD","LU1988902786.USD","MSDD","BK4560","WNTR","LMI3.UK","LU1235294995.USD","LU0642271901.SGD","LU0345774631.USD","BK4123","BK4548","LU0154245673.USD","LU0708995401.HKD","LU2543165471.USD","LU2125909247.SGD","IE00BBT3K403.USD","LU0109394709.USD","LU2290526834.HKD","LU2125909916.SGD","LU2286300806.USD","LU2272731782.SGD","LU1951200564.SGD","BK4079","LU0476273544.USD","LU1861215975.USD","MSST","BK4170","LU1069347547.HKD","LU0786609619.USD","MSOO","LU2272731865.HKD","3LMI.UK","LU1923623000.USD","BK4604","LU1035773651.USD","IE00BMPRXR70.SGD","LU2148611432.USD","BK4512","IMST","LU0006061336.USD","BK4534","BK4575","BK4600","LU0321505439.SGD","LU2433249047.HKD","LU0320765992.SGD","LU0203347892.USD","LU1720051017.SGD","LU2210150020.SGD","LU0127658192.USD","LU1261432733.SGD","LU0321505868.SGD","BK4529","IE00BLSP4452.SGD","LU2098885051.SGD","IE00B19Z9Z06.USD","BK4588","LU0187121727.USD","NDX","BK4141","LU0061475181.USD","BK4598","LU2125909759.SGD","LU2264538146.SGD","LU2360107168.USD","BK4528","IE0009356076.USD","LU1923622614.USD","MSTK","BK4579","LU2931357623.SGD","LU0444973449.USD","BK4581","LU1852331112.SGD","BK4596","GB00BDT5M118.USD","LU1267930730.SGD","LU1642822529.SGD","IE00B19Z9P08.USD","LU2106854487.HKD","LU2357305700.SGD","LU0672654240.SGD","DDOG","LU0097036916.USD","BK4543"],"gpt_icon":1}],"profile":{"websiteUrl":"http://www.alnylam.com","stockEarnings":[{"period":"1week","weight":-0.098},{"period":"1month","weight":-0.0837},{"period":"3month","weight":-0.2541},{"period":"6month","weight":0.1209},{"period":"1year","weight":0.4419},{"period":"ytd","weight":-0.0965}],"compareEarnings":[{"period":"1week","weight":-0.0035},{"period":"1month","weight":0.0302},{"period":"3month","weight":0.041},{"period":"6month","weight":0.1021},{"period":"1year","weight":0.1691},{"period":"ytd","weight":0.0143}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.031034},{"month":2,"riseRate":0.47619,"avgChangeRate":0.003609},{"month":3,"riseRate":0.47619,"avgChangeRate":-0.013154},{"month":4,"riseRate":0.380952,"avgChangeRate":-0.019703},{"month":5,"riseRate":0.619048,"avgChangeRate":0.04124},{"month":6,"riseRate":0.636364,"avgChangeRate":0.064494},{"month":7,"riseRate":0.681818,"avgChangeRate":0.106925},{"month":8,"riseRate":0.590909,"avgChangeRate":0.037005},{"month":9,"riseRate":0.545455,"avgChangeRate":0.034409},{"month":10,"riseRate":0.409091,"avgChangeRate":-0.042013},{"month":11,"riseRate":0.727273,"avgChangeRate":0.078577},{"month":12,"riseRate":0.454545,"avgChangeRate":0.006257}],"exchange":"NASDAQ","name":"Alnylam Pharmaceuticals","nameEN":"Alnylam Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Alnylam Pharmaceuticals(ALNY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Alnylam Pharmaceuticals(ALNY) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Alnylam Pharmaceuticals,ALNY,Alnylam Pharmaceuticals股票,Alnylam Pharmaceuticals股票老虎,Alnylam Pharmaceuticals股票老虎国际,Alnylam Pharmaceuticals行情,Alnylam Pharmaceuticals股票行情,Alnylam Pharmaceuticals股价,Alnylam Pharmaceuticals股市,Alnylam Pharmaceuticals股票价格,Alnylam Pharmaceuticals股票交易,Alnylam Pharmaceuticals股票购买,Alnylam Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Alnylam Pharmaceuticals(ALNY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Alnylam Pharmaceuticals(ALNY) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}